JP5753843B2 - p40依存性疾患の治療におけるベンジダミンの使用 - Google Patents
p40依存性疾患の治療におけるベンジダミンの使用 Download PDFInfo
- Publication number
- JP5753843B2 JP5753843B2 JP2012518870A JP2012518870A JP5753843B2 JP 5753843 B2 JP5753843 B2 JP 5753843B2 JP 2012518870 A JP2012518870 A JP 2012518870A JP 2012518870 A JP2012518870 A JP 2012518870A JP 5753843 B2 JP5753843 B2 JP 5753843B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- benzydamine
- physiologically acceptable
- acid addition
- free base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
特に、本発明は、サイトカインサブユニットp40の発現又は過剰発現に起因した炎症性疾患の治療におけるベンジダミンの使用に関する。
生体外でのp40 mRNA発現に対するベンジダミンの効果
生体外でのp40タンパク質産生に対するベンジダミンの効果
生体外でのTNFに対するベンジダミンの効果
斑性乾癬に対するベンジダミンの効果
次の表4〜9は本発明に係る医薬製剤の特定例を示す。
Claims (14)
- サイトカインサブユニットp40の発現に起因した炎症性疾患の治療用薬剤の製造におけるベンジダミン又はその生理学的に許容し得る酸付加塩の使用であって、
前記炎症性疾患が乾癬性関節炎および乾癬からなる群より選択される、使用。 - 前記薬剤が全身又は局所投与用に処方される請求項1に記載の使用。
- 前記全身投与用薬剤が、遊離塩基として表される1mg〜100mgの量のベンジダミン又はその生理学的に許容し得る酸付加塩を含む請求項2に記載の使用。
- 前記全身投与用薬剤が、遊離塩基として表される5mg〜50mgの量のベンジダミン又はその生理学的に許容し得る酸付加塩を含む請求項3に記載の使用。
- 前記局所投与用薬剤が、遊離塩基として表されるベンジダミン又はその生理学的に許容し得る酸付加塩を薬剤の総重量に対し1〜20重量%の量で含む請求項2に記載の使用。
- 前記局所投与用薬剤が、遊離塩基として表されるベンジダミン又はその生理学的に許容し得る酸付加塩を薬剤の総重量に対し1〜10重量%の量で含む請求項5に記載の使用。
- 前記炎症性疾患が乾癬性関節炎である請求項1に記載の使用。
- 前記炎症性疾患が乾癬である請求項1に記載の使用。
- サイトカインサブユニットp40の発現に起因した炎症性疾患の全身又は局所投与による治療用で、ベンジダミン又はその生理学的に許容し得る酸付加塩を含む医薬組成物であって、
前記炎症性疾患が乾癬性関節炎および乾癬からなる群より選択される、医薬組成物。 - 遊離塩基として表されるベンジダミン又はその生理学的に許容し得る酸付加塩を全身投与用として1mg〜100mgの量で含む請求項9に記載の医薬組成物。
- 遊離塩基として表されるベンジダミン又はその生理学的に許容し得る酸付加塩を全身投与用として5mg〜50mgの量で含む請求項10に記載の医薬組成物。
- 遊離塩基として表されるベンジダミン又はその生理学的に許容し得る酸付加塩を局所投与用として組成物の総重量に対し1〜20重量%の量で含む請求項9に記載の医薬組成物。
- 遊離塩基として表されるベンジダミン又はその生理学的に許容し得る酸付加塩を局所投与用として組成物の総重量に対し1〜10重量%の量で含む請求項12に記載の医薬組成物。
- 前記ベンジダミンの生理学的に許容し得る酸付加塩が、塩酸、臭化水素酸、硫酸、リン酸、硝酸、酢酸、アスコルビン酸、安息香酸、クエン酸、フマル酸、乳酸、マレイン酸、メタンスルホン酸、シュウ酸、パラトルエンスルホン酸、ベンゼンスルホン酸、コハク酸、タンニン酸及び酒石酸からなる群より選択した無機酸又は有機酸で得られる請求項9〜13のいずれかに記載の全身投与用又は局所投与用医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09425270.7 | 2009-07-08 | ||
EP09425270 | 2009-07-08 | ||
PCT/EP2010/058881 WO2011003737A1 (en) | 2009-07-08 | 2010-06-23 | USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012532173A JP2012532173A (ja) | 2012-12-13 |
JP5753843B2 true JP5753843B2 (ja) | 2015-07-22 |
Family
ID=41279454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012518870A Active JP5753843B2 (ja) | 2009-07-08 | 2010-06-23 | p40依存性疾患の治療におけるベンジダミンの使用 |
Country Status (26)
Country | Link |
---|---|
US (1) | US20120302618A1 (ja) |
EP (1) | EP2451452B1 (ja) |
JP (1) | JP5753843B2 (ja) |
KR (1) | KR101723996B1 (ja) |
CN (1) | CN102470125B (ja) |
AR (1) | AR077451A1 (ja) |
AU (1) | AU2010270425B2 (ja) |
BR (1) | BR112012000410B8 (ja) |
CA (1) | CA2760176C (ja) |
CY (1) | CY1116914T1 (ja) |
DK (1) | DK2451452T3 (ja) |
EA (1) | EA022862B1 (ja) |
ES (1) | ES2554332T3 (ja) |
GE (1) | GEP20146156B (ja) |
HK (1) | HK1165280A1 (ja) |
HR (1) | HRP20151393T8 (ja) |
HU (1) | HUE028220T2 (ja) |
IL (1) | IL216717A (ja) |
MX (1) | MX2012000498A (ja) |
PL (1) | PL2451452T3 (ja) |
PT (1) | PT2451452E (ja) |
SG (2) | SG176686A1 (ja) |
SI (1) | SI2451452T1 (ja) |
SM (1) | SMT201500277B (ja) |
UA (1) | UA105666C2 (ja) |
WO (1) | WO2011003737A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107873024A (zh) * | 2015-02-09 | 2018-04-03 | 塞尔利克斯生物私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
WO2017044752A1 (en) * | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Anti-fibrotic effect of cd70 |
WO2018007288A1 (en) * | 2016-07-08 | 2018-01-11 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Pharmaceutical composition comprising benzydamine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1054833A (ja) | 1963-08-09 | |||
IT1184123B (it) | 1985-01-22 | 1987-10-22 | Acraf | Impiego della benzidamina nel trattamento delle infezioni da trichomonas vaginalis e gardnerella vaginalis |
IT1276040B1 (it) * | 1993-07-27 | 1997-10-24 | Angelini Francesco Ist Ricerca | Uso della benzidamina nel trattamento di stati patologici causati dal tnf |
IT1274026B (it) | 1994-03-01 | 1997-07-14 | Acraf | Composizione antitosse |
IT1274655B (it) * | 1995-02-28 | 1997-07-18 | Smithkline Beecham Farma | Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico |
WO2006075123A1 (en) * | 2005-01-14 | 2006-07-20 | Camurus Ab | Topical bioadhesive formulations |
ATE462409T1 (de) * | 2005-01-14 | 2010-04-15 | Camurus Ab | Topische bioadhäsive formulierungen |
GB0604824D0 (en) * | 2006-03-09 | 2006-04-19 | Arakis Ltd | The treatment of inflammatory disorders |
-
2010
- 2010-06-23 SI SI201031052T patent/SI2451452T1/sl unknown
- 2010-06-23 DK DK10728191.7T patent/DK2451452T3/en active
- 2010-06-23 PT PT107281917T patent/PT2451452E/pt unknown
- 2010-06-23 ES ES10728191.7T patent/ES2554332T3/es active Active
- 2010-06-23 GE GEAP201012558A patent/GEP20146156B/en unknown
- 2010-06-23 MX MX2012000498A patent/MX2012000498A/es unknown
- 2010-06-23 EP EP10728191.7A patent/EP2451452B1/en active Active
- 2010-06-23 KR KR1020117031281A patent/KR101723996B1/ko active IP Right Grant
- 2010-06-23 US US13/382,450 patent/US20120302618A1/en not_active Abandoned
- 2010-06-23 WO PCT/EP2010/058881 patent/WO2011003737A1/en active Application Filing
- 2010-06-23 UA UAA201200082A patent/UA105666C2/uk unknown
- 2010-06-23 EA EA201270143A patent/EA022862B1/ru unknown
- 2010-06-23 BR BR112012000410A patent/BR112012000410B8/pt not_active IP Right Cessation
- 2010-06-23 HU HUE10728191A patent/HUE028220T2/en unknown
- 2010-06-23 AU AU2010270425A patent/AU2010270425B2/en not_active Ceased
- 2010-06-23 CN CN201080028333.5A patent/CN102470125B/zh not_active Expired - Fee Related
- 2010-06-23 JP JP2012518870A patent/JP5753843B2/ja active Active
- 2010-06-23 PL PL10728191T patent/PL2451452T3/pl unknown
- 2010-06-23 SG SG2011090032A patent/SG176686A1/en unknown
- 2010-06-23 CA CA2760176A patent/CA2760176C/en not_active Expired - Fee Related
- 2010-06-23 SG SG10201403088XA patent/SG10201403088XA/en unknown
- 2010-07-06 AR ARP100102406A patent/AR077451A1/es not_active Application Discontinuation
-
2011
- 2011-12-01 IL IL216717A patent/IL216717A/en active IP Right Grant
-
2012
- 2012-06-18 HK HK12105915.7A patent/HK1165280A1/zh not_active IP Right Cessation
-
2015
- 2015-11-06 SM SM201500277T patent/SMT201500277B/it unknown
- 2015-11-13 CY CY20151101024T patent/CY1116914T1/el unknown
- 2015-12-18 HR HRP20151393TT patent/HRP20151393T8/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101801864B1 (ko) | 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도 | |
US7879870B2 (en) | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists | |
CN108884053A (zh) | 预防和/或治疗与衰老有关的认知障碍和神经炎症的方法 | |
JP5753843B2 (ja) | p40依存性疾患の治療におけるベンジダミンの使用 | |
KR20190064583A (ko) | Chs-131로 다발성 경화증의 치료 | |
EP3884945A1 (en) | Glutarimide derivative for overcoming resistance to steriods | |
JPH1192382A (ja) | 細胞接着阻害剤 | |
WO2022253034A1 (zh) | 吡咯并嘧啶类化合物的用途 | |
JP2024511141A (ja) | オリスミラストによる化膿性汗腺炎の治療 | |
WO2021004229A1 (zh) | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 | |
US9962400B2 (en) | Methods and compositions for treating lupus | |
JPWO2020004404A1 (ja) | IL−1β阻害薬 | |
TW201938167A (zh) | 含有賽度替尼之外用皮膚醫藥組成物及其用途 | |
Elmarssafy et al. | Clinical Evaluation of Using Benzydamine Hydrochloride Oral Gel with Intralesional Corticosteroid Injection for Pain Control in Symptomatic Oral Lichen Planus | |
WO2022222948A1 (zh) | 包含jak3/jak1/tbk1选择性抑制剂的药物组合物及其医药用途 | |
Colombel et al. | DOP38 Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction Therapy | |
US20220233534A1 (en) | Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof | |
WO2023203022A1 (en) | Treatment of neutrophilic dermatoses | |
WO2021104034A1 (zh) | 对羟基苯甲醛于治疗发炎性肠道疾病的用途 | |
CN113230255A (zh) | 阿帕替尼在制备防治nlrp3炎症小体相关疾病的药物中的应用 | |
JPH11106337A (ja) | 乾癬の処置剤 | |
OA20849A (en) | Use of glutarimide derivative for overcoming steroid resistance and treating diseases associated with aberrant interferon gamma signaling. | |
CN111511359A (zh) | 非甾体选择性糖皮质激素受体激动调节剂(segram)及其用途 | |
Pump | Pr Taro-Imiquimod Pr Taro-Imiquimod Pump | |
PAPPS et al. | Therapies for psoriasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140718 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140722 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141125 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150325 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150406 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150512 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150525 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5753843 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |